- Effectiveness and safety of abiraterone acetate treatment for metastatic castration-resistant prostate cancer post-chemotherapy2018 | First Faculty of Medicine
- Abirateron acetate2017 | First Faculty of Medicine
- Vhodný pacient pro léčbu abirateron acetátem2017 | First Faculty of Medicine
- Efektivita a bezpečnost léčby abirateron acetátem u pacientů s metastatickým kastračně rezistentním karcinomem prostaty po chemoterapii - výsledky studie 212082PCR3001 v České republicePublication without faculty affiliation
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerPublication without faculty affiliation
- Preclinical evaluation of new formulation concepts for abiraterone acetate bioavailability enhancement based on the inhibition of pH-induced precipitation2020 | First Faculty of Medicine, Faculty of Science
- Expanded access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer post-chemoterapy - results in Czech RepublicPublication without faculty affiliation
- Research Report University Hospital for clinical assessment Go27983Publication without faculty affiliation
- Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate2024 | Faculty of Medicine in Pilsen
- Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience2023 | Faculty of Medicine in Pilsen
- Bioavailability Enhancement and Food Effect Elimination of Abiraterone Acetate by Encapsulation in Surfactant-Enriched Oil Marbles2020 | First Faculty of Medicine, Faculty of Science
- Pharmaceutical Product Characterization and Manufacturability of Surfactant-Enriched Oil Marbles with Abiraterone Acetate2022 | Faculty of Science
- Abiraterone acetate and quality of life of castration-resistant prostate cancer patients2013 | First Faculty of Medicine
- Report of University Hospital Hradec Králové to the clinical trial protocol No: 212082PCR3011Publication without faculty affiliation
- Analysis of european patients enrolled in a global early access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer progressing after chemotherapy2014 | First Faculty of Medicine
- Azobisisobutyronitrile loaded on mesoporous silica particles: A new stressor for solid-state oxidative forced degradation studies2023 | Faculty of Science, Central Library of Charles University
- Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial2015 | Second Faculty of Medicine
- Prognostic factors in metastatic prostate cancer2023 | First Faculty of Medicine
- The role of ARTA in metastatic hormon-naive prostate cancer treatment2022 | Third Faculty of Medicine
- New hormonal agents in castration-resistant prostate cancer2013 | First Faculty of Medicine
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer2017 | Faculty of Medicine in Hradec Králové
- New treatment options in hormone-sensitive prostate cancer +12019 | First Faculty of Medicine
- Current treatment options for metastatic castration-resistant prostate cancer2018 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Physical Education and Sport
- Validity of cycloheximide chylomicron flow blocking method for the evaluation of lymphatic transport of drugs2021 | First Faculty of Medicine, Faculty of Science
- Pharmacokinetic Variability in Pre-Clinical Studies: Sample Study with Abiraterone in Rats and Implications for Short-Term Comparative Pharmacokinetic Study Designs2022 | First Faculty of Medicine, Faculty of Science